stockportfolio.pro
Stocks / MRNA vs RMD
MRNA vs RMD
Moderna, Inc. and ResMed Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
RMD is the larger company ($27.0B vs $24.5B). On the fundamentals, MRNA grows revenue faster (19.3% vs 11.7%); RMD earns a higher net margin (27.2% vs -145.2%); RMD has the stronger return on equity (23.5% vs -32.6%). Full numbers below — the stronger figure on each row is in green.
| Moderna, Inc. (MRNA) | ResMed Inc. (RMD) | |
|---|---|---|
| Market cap | $24.5B | $27.0B |
| Revenue (latest FY) | $1.94B | $5.15B |
| Net income (latest FY) | $-2.82B | $1.40B |
| Revenue growth (5y CAGR) | 19.3% | 11.7% |
| Net margin | -145.2% | 27.2% |
| Return on equity | -32.6% | 23.5% |
| P/E ratio | — | 17.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 10 |
| Positive free cash flow | No | Yes |
Compare with another company:
See the full MRNA vs RMD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open MRNA's full financials → Open RMD's full financials →More comparisons
Frequently asked questions
Which is bigger, MRNA or RMD?
ResMed Inc. is larger by market capitalization — $27.0B versus $24.5B.
Which grows faster, MRNA or RMD?
Over the last five fiscal years, Moderna, Inc. grew revenue faster — 19.3%/yr versus 11.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.